<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02922582</url>
  </required_header>
  <id_info>
    <org_study_id>404-C-201</org_study_id>
    <nct_id>NCT02922582</nct_id>
  </id_info>
  <brief_title>Study of Local Administration of DepoTXA for Reduced Bleeding in Subjects Undergoing TKA</brief_title>
  <official_title>A Randomized, Single-Blind, Active-Controlled, Dose-Ranging Study To Evaluate PK, Safety, and Efficacy of Local Administration of DepoTXA for Reduced Post-Surgical Bleeding in Subjects Undergoing TKA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pacira Pharmaceuticals, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pacira Pharmaceuticals, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2, randomized, single-blind, active-controlled dose-ranging study in subjects
      scheduled to undergo total knee arthroplasty (TKA).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 45 subjects (15 per arm) are planned for enrollment. Subjects will be
      randomized in a 1:1:1 ratio to receive either DepoTXA 800 mg, DepoTXA 1200 mg, or IV TXA
      (CyklokapronÂ® 1 gram).
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow Enrollment
  </why_stopped>
  <start_date type="Actual">October 28, 2016</start_date>
  <completion_date type="Actual">November 16, 2017</completion_date>
  <primary_completion_date type="Actual">November 16, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total postsurgical opioid consumption in morphine equivalents</measure>
    <time_frame>through 48 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to first opioid rescue from PACU discharge</measure>
    <time_frame>through 7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of opioid-free subjects</measure>
    <time_frame>through 48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS pain intensity scores</measure>
    <time_frame>from 0 to 48 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Total Knee Arthroplasty</condition>
  <arm_group>
    <arm_group_label>IV Tranexamic acid (TXA)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 gram IV TXA intraoperatively at the end of surgery one time</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DepoTXA 800mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>800mg Intracapsular at the end of surgery one time</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DepoTXA 1200mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1200mg Intracapsular at the end of surgery one time</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DepoTXA</intervention_name>
    <arm_group_label>DepoTXA 800mg</arm_group_label>
    <arm_group_label>DepoTXA 1200mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <arm_group_label>IV Tranexamic acid (TXA)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Scheduled to undergo elective unilateral open TKA under general, spinal, or regional
             anesthesia.

          2. American Society of Anesthesiology (ASA) physical status 1, 2, or 3.

          3. Currently receiving anticoagulation or antiplatelet therapy for cardiovascular disease
             or thromboembolic risk.

          4. Female subject must be surgically sterile; or at least 2 years postmenopausal; or have
             a monogamous partner who is surgically sterile; or practicing double-barrier
             contraception; or practicing abstinence (must agree to use double-barrier
             contraception in the event of sexual activity); or using an insertable, injectable, or
             transdermal, contraceptive approved by the FDA for greater than 2 months prior to
             screening and commit to the use of an acceptable form of birth control for the
             duration of the study and for 30 days after completion of the study.

          5. Able to provide informed consent, adhere to the study visit schedule, and complete all
             study assessments.

        Exclusion Criteria:

          1. Currently pregnant, nursing, or planning to become pregnant during the study or within
             1 month after study drug administration.

          2. Planned concurrent surgical procedure (e.g., bilateral TKA).

          3. Prior open knee surgery on ipsilateral knee. Prior arthroscopy is permitted.

          4. Patients taking a medication with a known procoagulant effect (eg, combination
             hormonal contraceptives, Factor IX complex concentrates or anti-inhibitor coagulant
             concentrates, or all-trans retinoic acid).

          5. Contraindication or hypersensitivity to TXA.

          6. Known active intravascular clotting.

          7. Prior subarachnoid hemorrhage.

          8. History of epilepsy.

          9. History of impaired kidney function, chronic respiratory disease, rheumatoid
             arthritis, congenital coagulopathy, or loss of sensation in extremities.

         10. Renal insufficiency as indicated by serum creatinine &gt; upper limit of normal (by
             central laboratory assessment).

         11. Anemia (Hb level,10 g/dL)

         12. Uncontrolled anxiety, psychiatric, or neurological disorder that might interfere with
             study assessments.

         13. Acquired defective color vision.

         14. Malignancy in the last 2 years, with the exception of non-metastatic basal cell or
             squamous cell carcinoma of the skin or localized carcinoma in situ of the cervix

         15. Suspected or known history of drug or alcohol abuse within the previous year.

         16. Body weight ,50 kg (110 pounds) or a body mass index .44 kg/m2.

         17. Administration of an investigational drug within 30 days or 5 elimination half-lives
             of such investigational drug, whichever is longer, prior to study drug administration,
             or planned administration of another investigational product or procedure during the
             patient's participation in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hassan Danesi, MD</last_name>
    <role>Study Director</role>
    <affiliation>Pacira Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ortho Arizona</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85296</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kendall Regional Medical Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33175</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University/Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 28, 2016</study_first_submitted>
  <study_first_submitted_qc>October 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2016</study_first_posted>
  <last_update_submitted>December 11, 2017</last_update_submitted>
  <last_update_submitted_qc>December 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

